基于学习控制算法的餐前胰岛素剂量决策在成人2型糖尿病中的随机临床试验
该随机单盲试验在北京市一家三级转诊医院纳入糖化血红蛋白≥8.0%的成人2型糖尿病患者119例,1:1随机分入AP-A算法辅助医师调整餐前胰岛素剂量组(n=59)和常规医师治疗组(n=60);AP-A组目标范围内时间(TIR)72.4% vs 对照组71.2%,中位差1.33%(95%CI -6.00至10.94),达到非劣效(非劣效界值-7.5%);低于3.0 mmol/L时间(TBR)两组均为0.0%,亦非劣效。
要点
- AP-A组TIR为72.4%,对照组71.2%,中位差1.33%(95%CI -6.00至10.94),达非劣效。
- AP-A组与对照组TBR均为0.0%,中位差0.00%(95%CI 0.00%至0.00%),达非劣效。
- AP-A辅助医师调整餐前胰岛素剂量的血糖控制不劣于常规医师治疗。
核心结论
- 在成人2型糖尿病中,AP-A辅助医师调整餐前胰岛素剂量与常规医师治疗相比,血糖控制达到非劣效。
研究设计与样本
- 随机、单盲临床试验,在中国北京一家三级转诊医院开展。
- 共筛查140例,随机分配119例至AP-A组(n=59)或医师组(n=60)。
- 纳入标准为年龄18岁及以上、糖化血红蛋白A1c≥8.0%的2型糖尿病患者。
- 主要目标为比较两组传感器葡萄糖在3.9至10.0 mmol/L范围内的时间百分比(TIR)。
- 安全性通过传感器葡萄糖低于3.0 mmol/L的时间百分比(TBR)评估。
主要发现
- AP-A组TIR为72.4%(63.3%-82.1%),对照组为71.2%(54.9%-81.4%),中位差1.33%(95%CI -6.00至10.94),非劣效界值-7.5%。
- AP-A组TBR为0.0%(0.0%-0.0%),对照组为0.0%(0.0%-0.0%),中位差0.00%(95%CI 0.00%至0.00%),非劣效界值2.0%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: We propose an artificial-pancreas-like algorithm (AP-A) that could automatically determine the preprandial insulin dose based on intermittently scanned continuous glucose monitoring (isCGM) data trajectories in multiple dose injection (MDI) therapy. OBJECTIVE: We aim to determine whether preprandial insulin dose adjustments guided by the AP-A are as effective and safe as physician decisions. METHODS: We performed a randomized, single-blind, clinical trial at a tertiary, referral hospital in Beijing, China. Type 2 diabetes participants were eligible if they were aged 18 years or older, with a glycated hemoglobin A1c of 8.0% or higher. Eligible participants were randomly assigned (1:1) to the AP-A arm supervised by physician and the conventional physician treatment arm. The primary objective was to compare percentage time spent with sensor glucose level in 3.9 to 10.0 mmol/L (TIR) between the 2 study arms. Safety was assessed by the percentage time spent with sensor glucose level below 3.0 mmol/L (TBR). RESULTS: A total of 140 participants were screened, of whom 119 were randomly assigned to the AP-A arm (n = 59) or physician arm (n = 60). The TIR achieved by the AP-A arm was statistically noninferior compared with the control arm (72.4% [63.3%-82.1%] vs 71.2% [54.9%-81.4%]), with a median difference of 1.33% (95% CI, -6.00 to 10.94, noninferiority margin -7.5%). TBR was also statistically noninferior between the AP-A and control arms (0.0% [0.0%-0.0%] vs 0.0% [0.0%-0.0%]), respectively; median difference (95% CI, 0.00% [0.00%-0.00%], noninferiority margin 2.0%). CONCLUSION: The AP-A-supported physician titration of preprandial insulin dosage offers noninferior glycemic control compared with optimal physician care in type 2 diabetes.
引用
- Liu W, Cai D, Zhang R, et al. A Randomized Clinical Trial for Meal Bolus Decision Using Learning-based Control in Adults With Type 2 Diabetes. J Clin Endocrinol Metab. 2024. PMID: 38450556. doi:10.1210/clinem/dgae143
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。